(ENTL) (ENTL) Stock Price, News & Analysis

Company Overview

Entellus Medical, Inc. is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment. The Company's XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The MiniFESS family of surgical instruments includes eight devices designed to enable physicians to perform various surgical procedures. The Fiagon Image Guidance System (IGS) consists of a navigation unit, navigation sensor, software instruments and a patient localizer.

Key Stats

• Today's Range: $24.00 to $24.00
• 50-Day Range: $24.00 to $24.06
• 52-Week Range: $11.47 to $25.58
• Volume: N/A
• Average Volume: 178,331 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ENTL Stock Analysis - Frequently Asked Questions

How were (ENTL)'s earnings last quarter?

(ENTL) (NASDAQ:ENTL) issued its quarterly earnings results on Thursday, November, 3rd. The medical technology company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by $0.13. The company's revenue was up 20.9% compared to the same quarter last year.

When did (ENTL) IPO?

(ENTL) (ENTL) raised $70 million in an initial public offering on Friday, January 30th 2015. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Piper Jaffray served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What other stocks do shareholders of (ENTL) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (ENTL) investors own include Intersect ENT (XENT), Bristol Myers Squibb (BMY), (RLYP) (RLYP), Twitter (TWTR), Altisource Asset Management (AAMC), ACADIA Pharmaceuticals (ACAD) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

• Last Earnings: 11/03/2016
• Today: 7/18/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ENTL
• CIK: 1374128
• Web: www.entellusmedical.com
• Phone: +1-763-4631595
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A